> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-46/
- Published: 2021-07-11T12:00:00.000Z
- Updated: 2026-09-14T17:05:47.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149688

**Notice Corrected on 2 ANDA Withdrawals**  
*7/9/2021 Federal Register* notice: FDA is correcting a 12/2/2019 notice announcing the withdrawal of 21 ANDAs from multiple applicants. That notice included two ANDAs that had been previously withdrawn in an earlier notice. This notice corrects the error. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-12/pdf/2021-14717.pdf?ref=fdaweb.com).

**Regulatory Review Period for Teva’s Ajovy**  
*7/9/2021 Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Teva Pharmaceuticals’ Ajovy (fremanezumab-vfrm), indicated for preventing migraines in adults. The regulatory review period is 3,216 days, which includes 2,882 days that occurred during the testing phase and 334 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-09/pdf/2021-14652.pdf?ref=fdaweb.com).

**HHS Withdraws Insulin Reimportation Notice**  
*7/9/2021 Federal Register* notice: HHS has withdrawn a 1/21 notice entitled “Requests for Proposals for Insulin Reimportation and Personal Prescription Drug Importation.” It is also withdrawing associated requests for proposals issued on its Web site. The department says it is not aware that any proposals were received in response to these notices. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-09/pdf/2021-14637.pdf?ref=fdaweb.com).

**Guide on Unique Device Identifier Info**  
*7/8/2021 Federal Register* notice: FDA has made available a final guidance entitled *Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI)*. The document describes the requirements and recommendations for UDIs. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14462.pdf?ref=fdaweb.com).

**Regulatory Review Period for Zephyr Valve Implant**  
*7/7/2021 Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Pulmonx Corp.’s Zephyr Endobronchial Valve Implant, indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The regulatory review period is 5,744 days, which includes 5,565 days that occurred during the testing phase and 179 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14482.pdf?ref=fdaweb.com).